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ABSTRACT
OBJECTIVE: To evaluate metabolic changes associated with highly active 
antiretroviral therapy (HAART) in HIV-positive patients, and to identify risk 
factors associated.
METHODS: Retrospective study that included 110 HIV-positive patients 
who where on HAART in the city of Porto Alegre (Southern Brazil) between 
January 2003 and March 2004. Data on demographic variables, cigarette 
smoking, diabetes mellitus, cholesterol and triglyceride levels, stage of HIV 
infection, antiretroviral therapy and HCV coinfection were collected. General 
linear models procedure for repeated measures was used to test the interaction 
between HAART and HCV coinfection or protease inhibitor treatment.
RESULTS: Total cholesterol, triglycerides, and glucose levels signifi cantly 
increased after receiving HAART (p<0.001 for all variables), but no 
interaction with protease inhibitors was seen for total cholesterol, glucose 
and triglyceride levels (interaction treatment*protease inhibitors p=0.741, 
p=0.784, and p=0.081, respectively). An association between total cholesterol 
levels and HCV coinfection was found both at baseline and follow-up (effect 
of HCV coinfection, p=0.011). Glucose levels were increased by HAART 
(treatment effect, p=0.036), but the effect was associated to HCV coinfection 
(treatment*HCV effect, p=0.018). Gender, smoking habit, intravenous drug 
use and age were not signifi cantly associated with cholesterol, triglyceride 
and glucose changes.
CONCLUSIONS: HCV-infected patients at baseline were signifi cantly less 
likely to develop hypercholesterolemia. The results provide further evidence 
of the role of HAART for the development of metabolic disturbances.
DESCRIPTORS: HIV Infections, prevention & control. Anti-HIV 
Agents, adverse effects. Comorbidity. Hepatitis C. Lipid Metabolism. 
Cholesterol, blood. Epidemiologic Studies.
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Adverse drug reactions are one of the important factors 
associated with reduced quality of life among HIV-
infected patients taking highly active antiretroviral 
therapy (HAART).18 Abnormalities in lipid metabo-
lism make HIV-positive patients subject to high risk 
for the development of coronary heart disease.2 The 
mechanisms responsible for metabolic changes of 
anti-HIV drugs are not fully understood. Increases in 
serum triglycerides, low-density lipoproteins (LDL), 
and total cholesterol have been reported as well as the 
development of insulin resistance.5
Lipid disturbances in HIV patients receiving protease 
inhibitor (PI) treatment are more evident.13 Deeks et al7 
(1997), in a 32-week study, identifi ed persistent eleva-
tions in cholesterol of 30%–40% from baseline and 
in triglycerides of 200%–300% from baseline. It has 
been reported that ritonavir increases the production of 
very low-density lipoprotein cholesterol (VLDL), trig-
RESUMO
OBJETIVO: Avaliar as alterações metabólicas associadas à terapia anti-retroviral 
potente em pacientes HIV-positivos e identifi car fatores de risco associados.
MÉTODOS: Estudo retrospectivo com 110 pacientes HIV-positivos que estavam 
sob terapia anti-retroviral potente (HAART) na cidade de Porto Alegre (RS), 
entre janeiro de 2003 e março de 2004. Os dados coletados incluem variáveis 
demográfi cas, tabagismo, diabetes mellitus, níveis de colesterol e triglicerídeos, 
estágio da infecção viral, terapia anti-retroviral e co-infecção com hepatite C. A 
análise multivariada para medidas repetidas (General Linear Model procedure 
for Repeated Measures) foi utilizada para testar a interação entre o efeito do uso 
de HAART e o uso de inibidores de protease ou co-infecção por hepatite C.
RESULTADOS: Foram observados aumentos signifi cativos nos níveis de 
colesterol total, triglicerídeos e glicose após o tratamento com HAART 
(p<0.001, para todas as variáveis). No entanto, nenhuma interação do tratamento 
com inibidores de protease foi observada para colesterol total, glicose e 
triglicerídeos (interação tratamento*inibidores de protease p=0.741, p=0.784 e 
p=0.081, respectivamente). Uma associação entre os níveis de colesterol total e 
co-infecção por HCV foi observada tanto antes como após o tratamento (efeito 
da co-infecção por hepatite C, p=0.011). Os níveis de glicose foram aumentados 
pelo uso da HAART (efeito do tratamento, p=0.036), sendo este dependente da 
co-infecção por hepatite C (efeito interação tratamento*hepatite C = 0.018). 
Gênero, tabagismo, uso de drogas intravenosas e idade não infl uenciaram 
signifi cativamente os níveis de colesterol total, triglicerídeos e glicose durante 
o tratamento.
CONCLUSÕES: Pacientes infectados pelo vírus da hepatite C no início do 
tratamento tiveram aumento menos signifi cativo nos níveis de colesterol total. 
Os resultados reforçam as evidências do papel da HAART no desenvolvimento 
de desordens metabólicas.
DESCRITORES: Infecções por HIV, prevenção & controle. Agentes 
Anti-HIV, efeitos adversos. Comorbidade. Hepatite C. Metabolismo dos 
Lipídeos. Colesterol, sangue. Estudos Epidemiológicos.
INTRODUCTION
lycerides, and apolipoprotein (apo) B in HIV-negative 
subjects indicating that treatment with this protease 
inhibitor in the absence of HIV infection can cause 
dyslipidemia.19 These observations have motivated 
researchers to investigate whether it is safe to switch 
patients with a PI-based regimen and optimal viral sup-
pression to a simplifi ed maintenance therapy (SMT) to 
reduce side effects and metabolic disturbances.4
The objective of the present study was to describe both 
metabolic changes associated with HAART and risk 
factors associated in HIV-positive patients.
METHODS
A retrospective cohort study was conducted includ-
ing 110 HIV-positive subjects who were on HAART 
at a reference laboratory in the city of Porto Alegre, 
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Southern Brazil. Of all 200 subjects, we selected 
all subjects with at least one follow-up lipid profi le 
between January 2003 and March 2004. Data (drug 
treatments, symptoms, HAART duration, time of HIV 
exposure or HIV diagnosis, laboratory results, and 
patient demographics) were collected through local 
database search. Data for hepatitis C virus (HCV) and 
tuberculosis coinfection were identifi ed by laboratory 
testing. The diagnoses of diabetes and hypertension 
were defi ned as specifi c guidelines.20,21 Further exclu-
sion criteria were secondary hyperlipidemia due to 
renal, hepatic or thyroid disease, and diabetes or fasting 
blood glucose levels above 110 mg/dL. Individuals that 
were on lipid-lowering medications were also excluded. 
Disease classifi cation was based on the National Sexu-
ally Transmitted Diseases (STD) and AIDS Program of 
the Brazilian Ministry of Health.a
Continuous variables were expressed as mean (standard 
deviation, SD) or median (interquartile range) when 
no normal distribution was assumed. A general linear 
models procedure for repeated measures using type III 
sums of squares statistics was used to test the interaction 
between HAART and HCV coinfection or PI treatment. 
This sum of squares applies to unbalanced study designs 
and measures the effect of an independent variable (HCV 
coinfection or PI treatment) after adjustment for all other 
covariables included in the model. To test the interaction 
between HAART and HCV coinfection or PI treatment 
two different multivariate models were applied. Age, 
gender, CD4 levels, HIV-RNA measurements, HAART 
duration were included in both models as covariables. 
HCV coinfection was included as a covariable to test 
the interaction between HAART and PI treatment and 
PI treatment was included as a covariable to test the in-
teraction between HAART and HCV coinfection. A 5% 
signifi cance level was set. All statistical analyses were 
performed using the SPSS package v. 13.0.
The study was approved by the Ethics Committee of 
Fundação Estadual de Produção e Pesquisa em Saúde 
(nº 2004-373H). Written informed consent was obtained 
from all subjects.
RESULTS
Table 1 shows the demographic characteristics, 
concomitant diseases and lipid, glucose, CD4 and 
HIV-RNA measurements of HIV-positive subjects 
taking non-nucleoside reverse transcriptase inhibitors 
Table 1. Baseline characteristics of subjects treated with highly active antiretroviral therapy (HAART). Porto Alegre, Southern 
Brazil, 2003–2004.
Characteristic
Overall NNRTI PI
n(%)a n(%)a n(%)a
Number of subjects 110 86 24
Time of HIV exposure (months) [median (IQR)] 28 (25-32) 26 (24-31) 29 (27-32)
Follow-up duration (months) [median (IQR)] 14 (2-16) 13 (4-16) 14 (2-16)
Female sex 55 (49.5) 40 (46.5) 14 (58.3)
Age (years) [mean (SD)] 37.2 (9.5) 37.7 (10.0) 34.8 (7.3)
Source of HIV exposure
Intravenous drug use 28 (25.2) 21 (24.4) 7 (29.2)
Homosexual 15 (13.5) 10 (11.6) 5 (20.9)
Heterosexual 59 (53.2) 46 (53.5) 12 (50.0)
Transfusion 5 (4.5) 5 (5.8) 0 (0.0)
Other 4 (3.6) 4 (4.7) 0 (0.0)
CD4 cells/mm3 [median (IQR)] 225 (164-289) 225 (174-289) 225 (136-301)
HIV-RNA log10 copies/mL [median (IQR)] 4.3 (3.7-4.8) 4.2 (3.7-4.7) 4.5 (3.9-4.9)
Current smoker 59 (54.1) 43 (51.2) 15 (62.5)
Hypertension 3 (3.5) 2 (3.0) 1 (5.6)
Diabetes mellitus 2 (2.4) 2 (3.0) 0 (0.0)
Tuberculosis 15 (13.5) 13 (15.1) 2 (8.3) 
Hepatitis C 19 (22.4) 15 (22.4) 4 (22.2)
a Except where indicated otherwise.
NNRTI: non-nucleoside reverse transcriptase; PI: protease inhibitors; IQR: interquartile range; SD: Standard deviation
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(NNRTI group) and protease inhibitors (PI group). 
The median follow-up was 14 months (interquartile 
range 2-16 months). Overall, 54 subjects (49%) were 
female and mean age was 37 years (SD =10 years, 
median = 36 years). The therapy group receiving 
NNRTI-containing HAART included 86 subjects, 
while the group receiving PI treatment consisted of 
24 subjects. Mean CD4 cell count was 225/mm3 in 
both groups. The most frequent concomitant diseases 
were: hypertension (3.5%), diabetes mellitus (2.4%), 
tuberculosis (13.5%), and hepatitis C (22.4%). None 
of the variables differed between NNRTI group and 
PI group (p>0.05 for all comparisons).
Details on the antiretroviral drugs used in the study 
are given in Table 2. The NNRTI-containing regimen 
including zidovudine, lamivudine and efavirenz was the 
most frequently prescribed (62.8%). For PI-containing 
regimens, the most common combination was zidovu-
dine, lamivudine, and nelfi navir (41.7%).
Total cholesterol >200 mg/dL was seen only in 7.2% 
of subjects at baseline, and in 25.5% of subjects on 
HAART. Similar results were found for triglyceride 
and glucose levels. Triglyceride levels >150 mg/dL 
were seen in 20.9% of subjects at baseline and in 32.7% 
during follow-up. Eight percent and 20.0% of subjects 
were hyperglycemic (glucose >110 mg/dL) at baseline 
and during follow-up, respectively. There were no risk 
differences between PI and NNRTI treatments for the 
development of hypercholesterolemia (RR=0.78, 95% 
CI = 0.33;1.83), hyperglycemia (RR=1.05, 95% CI = 
0.43;2.56) or hypertriglyceridemia (RR=1.37, 95% CI 
= 0.78;2.44) during follow-up. Similar results were 
found for HCV coinfection (Table 3).
Table 4 and the Figure provide adjusted lipid and 
glucose levels at baseline and follow-up for PI treat-
ment and HCV coinfection. There were signifi cant 
increases in total cholesterol, triglyceride and glucose 
levels after receiving HAART (effect of treatment, 
p<0.001 for all variables), but no interaction with PI 
treatment was seen for total cholesterol (interaction 
treatment*PI p=0.741, Figure 1A), glucose (interac-
tion treatment*PI p=0.784, Figure 1B) or triglyceride 
levels (interaction treatment*PI p=0.081, Figure 1C). 
Table 2. Non-nucleoside reverse transcriptase and protease 
inhibitor-containing regimens used in the study. Porto Alegre, 
Southern Brazil, 2003–2004.
HAART Regimen n (%)
NNRTI (n=86) EFV + 3TC + AZT 54 (62.8%)
EFV + 3TC + d4T 17 (19.8%)
NVP + AZT + 3TC 13 (15.1%)
EFV + 3TC + TNF 1 (1.2%)
NVP + 3TC + d4T 1 (1.2%)
PI (n=24) NFV + AZT + 3TC 10 (41.7%)
LPV + RTV + AZT + 3TC 7 (29.2%)
ATV + AZT + 3TC 3 (12.5%)
NFV + d4T + 3TC 2 (8.3%)
LPV + RTV +TC + ABC 2 (8.3%)
NNRTI: non-nucleoside reverse transcriptase; AZT: 
zidovudine; ATV: atazanavir; EFV: efavirenz; NVP: nevirapine; 
3TC: lamivudine; d4T: estavudine; TNF: tenofovir; NFV: 
nelfi navir, LPV: lopinavir; RTV: ritonavir; ABC: abacavir; PI: 
protease inhibitors
Table 3. Incidence and relative risk for total cholesterol >200 mg/dL, glucose >110 mg/dL and triglyceride >150 mg/dL. Porto 
Alegre, Southern Brazil, 2003–2004.
Variable n TC >200 mg/dL Glucose >110 mg/dL TG >150 mg/dL
Overall 110
Baseline 8 (7.2%) 9 (8.1%) 23 (20.9%)
Follow-up 28 (25.5%) 22 (20.0%) 36 (32.7%)
Follow-up
PI treatment
No 86 23 (26.7%) 17 (19.8%) 26 (30.2%)
Yes 24 5 (20.8%) 5 (20.8%) 10 (41.7%)
RR (95% CI)a 0.78 (0.33;1.83) 1.05 (0.43;2.56) 1.37 (0.78;2.44)
HCV coinfection
No 92 26 (28.3%) 20 (21.7%) 32 (34.8%)
Yes 18 2 (11.1%) 2 (11.1%) 5 (27.8%)
RR (95% CI)a 0.39 (0.10;1.52) 0.51 (0.13;1.99) 0.79 (0.36;1.77)
a Relative risk (95% confi dence interval)
TC: total cholesterol
TG: triglycerides
PI: protease inhibitor
HCV: hepatitis C virus
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These results show a HAART effect on metabolic 
changes regardless of the antiretroviral regimen used. 
The same approaches were applied to investigate the 
effects of HCV coinfection on lipid and glucose pa-
rameters. For HCV coinfection, after controlling for 
age, gender, CD4 levels, HIV-RNA measurements, 
HAART duration and PI treatment, signifi cant in-
creases in total cholesterol, triglyceride and glucose 
levels after receiving HAART (effect of treatment, 
p<0.001 for total cholesterol levels and p<0.05 for 
glucose and triglyceride levels) were evidenced. An 
association between total cholesterol levels and HCV 
coinfection was seen both at baseline and follow-up 
(effect of HCV coinfection p=0.011). At baseline, 
HCV-positive subjects had lower total cholesterol lev-
els (141.7±33.2 mg/dL) than HCV-negative subjects 
(156.6±37.4 mg/dL). The same results were found 
during follow-up (157.3 ± 31.8 mg/dL and 183.0±38.5 
Table 4. Estimated marginal means for total cholesterol, glucose and triglyceride levels analyzed by general linear models 
procedure for repeated measures. Porto Alegre, Southern Brazil, 2003–2004.
Variable Category Mean (SD) n Effect p-value
Protease inhibitor
TC
No Baseline 153.4 (37.0) 86 Treatment <0.001
Follow-up 177.3 (37.4) PI 0.558
Yes Baseline 156.3 (38.3) 24 Treatment*PI 0.741*
Follow-up 183.3 (43.6)
Glucose
No Baseline 92.5 (17.9) 86 Treatment <0.001
Follow-up 100.6 (14.4) PI 0.631
Yes Baseline 91.7 (8.1) 24 Treatment*PI 0.784*
Follow-up 98.7 (11.2)
TG
No Baseline 122.4 (62.4) 86 Treatment <0.001
Follow-up 147.4 (125.9) PI 0.776
Yes Baseline 109.6 (42.4) 24 Treatment*PI 0.081*
Follow-up 164.5 (141.4)
HCV coinfection TC
TC
No Baseline 156.6 (37.4) 92 Treatment <0.001
Follow-up 183.0 (38.5) HCV 0.011
Yes Baseline 141.7 (33.2) 18 Treatment*HCV 0.292*
Follow-up 157.3 (31.8)
Glucose
No Baseline 91.4 (15.3) 92 Treatment 0.036
Follow-up 100.9 (13.9) HCV 0.790
Yes Baseline 97.3 (19.8) 18 Treatment*HCV 0.018*
Follow-up 96.7 (12.1)
TG
No Baseline 120.8 (61.8) 92 Treatment 0.029
Follow-up 156.6 (139.2) HCV 0.732
Yes Baseline 114.5 (39.2) 18 Treatment*HCV 0.397*
Follow-up 124.9 (43.2)
* Statistically signifi cant
TC: total cholesterol
TG: triglycerides
PI: protease inhibitor
HCV: hepatitis C virus
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mg/dL, respectively), showing an effect of HCV 
coinfection on total cholesterol levels regardless of 
HAART (Figure 1D). Glucose levels were increased 
by HAART (treatment effect p=0.036), but the effect 
was associated to HCV coinfection. HCV-negative 
subjects showed an increase of 10.4% in glucose 
levels, whereas HCV-positive subjects had similar 
glucose levels regardless of HAART (effect of HCV 
coinfection*treatment = 0.018, Figure 1E). No effect 
of HCV coinfection was seen for triglyceride levels 
(effect of HCV coinfection = 0.732, effect of HCV 
coinfection*treatment = 0.397, Figure 1F).
Figure. Adjusted marginal means for total cholesterol, glucose, and triglyceride levels (mg/dL) in antiretroviral-naïve subjects tre-
ated with HAART by PI treatment (A, B and C) and HCV coinfection (D, E and F). Porto Alegre, Southern Brazil, 2003–2004.
Es
tim
at
ed
 M
ar
gi
na
l M
ea
ns
 T
C
 (m
g/
dL
)
Es
tim
at
ed
 M
ar
gi
na
l M
ea
ns
 T
C
 (m
g/
dL
)
180
170
160
150
Yes
No
PI treatment
Baseline Follow-up
A 
190
180
170
160
150
140
Yes
No
HCV coinfection
Baseline Follow-up
D 
Es
tim
at
ed
 M
ar
gi
na
l M
ea
ns
 G
lu
co
se
 (m
g/
dL
)
Es
tim
at
ed
 M
ar
gi
na
l M
ea
ns
 G
lu
co
se
 (m
g/
dL
)
105
102
99
96
93
90
Yes
No
PI treatment
Baseline Follow-up
B 102
100
98
96
94
92
90
Yes
No
HCV coinfection
Baseline Follow-up
E 
Es
tim
at
ed
 M
ar
gi
na
l M
ea
ns
 T
G
 (m
g/
dL
)
Es
tim
at
ed
 M
ar
gi
na
l M
ea
ns
 T
G
 (m
g/
dL
)180
160
140
120
100
Yes
No
PI treatment
Baseline Follow-up
C 
160
150
140
130
120
110
Yes
No
HCV coinfection
Baseline Follow-up
F 
289Rev Saúde Pública 2009;43(2):283-90
DISCUSSION
Data about the effect of HAART on metabolic changes 
in Brazilian HIV-positive patients are scarce. Data for 
other populations showed that multidrug antiretroviral 
therapy, including the use of protease inhibitors, is as-
sociated with dyslipidemia,2-12,15 a well-recognized risk 
factor for the development of coronary artery disease.10 
Previous studies have indicated a broad variation in 
hypercholesterolemia and hypertriglyceridemia rates 
among HIV-positive patients on diverse highly-active 
antiretroviral therapy regimens. Lipid disorders are fre-
quently associated with protease inhibitor treatment.11 
However, emerging evidences indicated an association 
between NNRTI-containing regimens and dyslipidemia 
and other metabolic changes.11 Hypercholesterolemia 
has been seen in almost 30% of PI-treated subjects and 
23% of NNRTI users, while hypertriglyceridemia has 
been seen in 40% and 32% of patients, respectively. In 
our study both PI-containing and NNRTI-containing 
HAART increased total cholesterol, triglyceride and 
glucose levels compared to baseline, regardless of 
PI-containing HAART. In our study nelfi navir was 
the most frequent PI used (50% of PI-containing 
regimens). A recent clinical trial comparing atazana-
vir with nelfi navir showed that the latter was more 
strongly associated to increases in total cholesterol, 
LDL-cholesterol and triglycerides.16
The role of HCV coinfection in the development of 
metabolic complications or in the response to anti-
retroviral treatment in HIV-positive patients remains 
incompletely understood. In our data, total cholesterol 
levels were signifi cantly lower in HIV-HCV coinfected 
patients on antiretroviral therapy. Previous investiga-
tions reported that patients infected with hepatitis C 
at baseline were signifi cantly less likely to develop 
hyperlipidemia.6,5,17 Interestingly, the presence of HCV 
coinfection during HIV treatment was also associated to 
higher insulin resistance, activated platelets, endothelial 
perturbation8 and lipodystrophy.6,9 Moreover, HCV 
coinfection was associated to treatment discontinuation 
and interruption.1,3,14 The mechanism underlying the 
protective effect of hepatitis C in the risk of develop-
ing hyperlipidemia is not known, but might refl ect an 
impaired total cholesterol synthesis in the liver or total 
cholesterol hypercatabolism.
The limitations of our study include the retrospective 
cohort design (with high rates of missing data), dispro-
portionately smaller number of patients in the PI-group, 
and absence of HIV-negative controls. In addition, data 
concerning other risk factors for coronary heart disease 
were not obtained in our study, including genetic fac-
tors, body mass index, plasma HDL and LDL levels, 
physical activity, and diet. To elucidate how antiretrovi-
ral therapy is associated to metabolic disturbances and 
could contribute to premature cardiovascular disease 
is of major importance. Therefore further research with 
larger sample size and detailed information regarding 
additional risk factors for coronary heart disease are 
necessary to better understand the effects of HAART.
In conclusion, our results provide further evidence of 
the role of HAART in lipid disorder development and 
emphasize the importance of analyzing the effect of 
antiretroviral therapy in different populations. In Brazil, 
the treatment of HIV-infected patients is provided by 
the government. Thus evidences found in our study 
may be useful to propose new guidelines for managing 
the metabolic changes during antiretroviral therapy. 
Moreover, our study found a signifi cant relationship 
between HIV-HCV coinfection and HAART effects on 
total cholesterol and glucose levels. In this regard, fur-
ther studies are needed to clarify the exact role of HCV 
infection in the induction of such abnormalities.
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